Safety Study of an Oral Vaccine to Prevent Seasonal Influenza
Randomized Phase 1 Double-Blinded Placebo Controlled Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Seasonal Influenza A Vaccine and dsRNA Adjuvant Administered Orally to Healthy Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Low and mid dose study was conducted under protocol number VXA02-001
High dose study was conducted under protocol number VXA02-003
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Cypress, California, United States, 90630
- WCCT
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- In good health as established by medical history, physical examination, and laboratory testing at the time of enrollment.
Exclusion Criteria:
- Positive for H1 influenza by HAI.
- Has had an influenza vaccine in the past 2 years.
- Current history of chronic alcohol consumption and/or illicit and/or recreational drug use.
- History of any confirmed or suspected immunodeficient or immunosuppressive condition
- Positive serology for HIV, HCV, or HBV
- Previous serious reactions to vaccination such as anaphylaxis, respiratory problems, hives, or abdominal pain.
- History of irritable bowel disease or other inflammatory digestive or gastrointestinal conditions that could affect the intended distribution of the vaccine targeting the mucosa of the small intestine
- Use of proton pump inhibitors(Nexium, Prilosec).
- Stool sample with occult blood at baseline exam
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Low Dose VXA-A1.1 Oral Vaccine
Two doses of replication incompetent adenovirus vaccine given in an oral tablet formulation.
|
One or two doses of replication incompetent adenovirus oral tablet vaccine
Other Names:
|
|
PLACEBO_COMPARATOR: VXA Placebo Tablet
Oral tablets of the same size and number as the vaccine tablet doses.
Placebo arms were included during enrollment of each of the experimental dose groups to maintain the double-blind study design.
|
Off-white tablets similarly formulated to the active drug product tablets.
Other Names:
|
|
EXPERIMENTAL: Medium Dose VXA-A1.1 Oral Vaccine
Two doses of replication incompetent adenovirus vaccine given in an oral tablet
|
One or two doses of replication incompetent adenovirus oral tablet vaccine
Other Names:
|
|
EXPERIMENTAL: High Dose VXA-A1.1 Oral Vaccine
One dose of replication incompetent adenovirus given in an oral tablet dose.
This dose was studied under protocol VXA02-003.
|
One or two doses of replication incompetent adenovirus oral tablet vaccine
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety of an oral vaccine tablet as measured by reported solicited (reactogenicity) and unsolicited adverse events
Time Frame: One year following last vaccination
|
One year following last vaccination
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Magnitude of humoral immune response to influenza as measured by functional assays
Time Frame: 28 Days and 180 Days post-vaccination
|
28 Days and 180 Days post-vaccination
|
|
Magnitude of cellular immune responses to influenza as measured by functional assays
Time Frame: 28 Days and 180 Days post-vaccination
|
28 Days and 180 Days post-vaccination
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Apinya Vutikullird, DO, WCCT
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- VXA02-001 & VXA02-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.